AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
AbbVie Gets CHMP Nod for Psoriasis Candidate Risankizumab
by Zacks Equity Research
AbbVie (ABBV) gets positive opinion of the CHMP recommending marketing approval for risankizumab for the treatment of moderate-to-severe plaque psoriasis.
Top Research Reports for Intel, AbbVie & United Technologies
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), AbbVie (ABBV) and United Technologies (UTX).
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Momenta (MNTA) Q4 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Momenta (MNTA) reported a narrower loss in Q4, while sales came ahead of expectations.
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie
AbbVie Extends Deal With Voyager to Make Parkinson's Drugs
by Zacks Equity Research
AbbVie (ABBV) expands its collaboration with Voyager Therapeutics to develop potential vectorized antibodies for Parkinson's disease (PD) and other synucleinopathies.
Why Is AbbVie (ABBV) Down 6.8% Since Last Earnings Report?
by Zacks Equity Research
AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pharma Stock Roundup: MRK Buys IMDZ, FDA Grants Priority Review to Some Candidates
by Zacks Equity Research
Merck (MRK) to buy Immune Design for $300 million. FDA grants priority review to regulatory applications filed by Merck, Roche (RHHBY) and AbbVie (ABBV).
AbbVie's RA Candidate Upadacitinib Gets FDA Priority Review
by Zacks Equity Research
AbbVie's (ABBV) new drug application for its late-stage candidate, upadacitinib, gets a priority review status from the FDA for treating rheumatoid arthritis in adult patients.
Roche's (RHHBY) BLA for Lymphoma Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) BLA for polatuzumab vedotin and NDAs for entrectinib, and grants Priority Review status to the applications.
AbbVie (ABBV) is a Top Dividend Stock Right Now: Should You Buy?
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma
by Zacks Equity Research
AbbVie (ABBV) enters a global strategic transaction agreement with privately-held Teneobio to develop and commercialize the latter's pre-clinical immunotherapy candidate, TNB-383B, as a multiple myeloma treatment.
Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies
by Zacks Equity Research
Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.
Roche (RHHBY) 2018 Sales Up on Solid New Drugs Performance
by Zacks Equity Research
Roche's (RHHBY) performance in 2018 is driven by solid strength in new drugs, which more than offset competition from biosimilars.
The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, AbbVie and General Dynamics
Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY
by Zacks Equity Research
Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.
Top Research Reports for Union Pacific, AbbVie & General Dynamics
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), AbbVie (ABBV) and General Dynamics (GD).
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $77.47, marking a +0.43% move from the previous day.
Biogen (BIIB) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the fourth quarter of 2018, driven by higher sales of Spinraza.
AbbVie's Imbruvica Combo Gets FDA Nod in First-Line Setting
by Zacks Equity Research
AbbVie's (ABBV) key cancer drug, Imbruvica, in combination with Gazyva, gets FDA approval for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in first-line setting.
Drug/Biotech Stock Earnings on Jan 29: PFE, AMGN, BIIB & AGN
by Zacks Equity Research
Four drug/biotech stocks are scheduled to release their fourth-quarter results on Jan 29. Let's take a look at how these companies are poised ahead of their earnings release.
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, Bristol-Myers, Lilly, AbbVie and Merck
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Congressional Activities on Shutdown in Focus
by Zacks Equity Research
Congressional Activities on Shutdown in Focus
AbbVie (ABBV) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
AbbVie (ABBV) misses estimates for both earnings and revenues in fourth quarter. Biosimilar competition impacts Humira sales in ex-U.S. markets. Imbruvica and Mavyret offset Humira decline.